Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Other Non-Current Liabilities (2020 - 2025)

Historic Other Non-Current Liabilities for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $10.1 million.

  • Tarsus Pharmaceuticals' Other Non-Current Liabilities rose 71838.71% to $10.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.1 million, marking a year-over-year increase of 71838.71%. This contributed to the annual value of $1.7 million for FY2023, which is 164800.0% up from last year.
  • Tarsus Pharmaceuticals' Other Non-Current Liabilities amounted to $10.1 million in Q3 2025, which was up 71838.71% from $1.2 million recorded in Q3 2024.
  • Tarsus Pharmaceuticals' 5-year Other Non-Current Liabilities high stood at $10.1 million for Q3 2025, and its period low was $40000.0 during Q1 2023.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $802000.0 (2021), whereas its average is $1.5 million.
  • In the last 5 years, Tarsus Pharmaceuticals' Other Non-Current Liabilities crashed by 9193.55% in 2023 and then surged by 391500.0% in 2024.
  • Quarter analysis of 5 years shows Tarsus Pharmaceuticals' Other Non-Current Liabilities stood at $699000.0 in 2021, then crashed by 85.69% to $100000.0 in 2022, then surged by 1648.0% to $1.7 million in 2023, then fell by 29.06% to $1.2 million in 2024, then soared by 718.39% to $10.1 million in 2025.
  • Its Other Non-Current Liabilities was $10.1 million in Q3 2025, compared to $1.2 million in Q3 2024 and $1.4 million in Q2 2024.